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Abstract 
• Background: Patients undergoing critical care can experience negative outcomes due to a 
variety of causes such as lack of sleep, prolonged pain, and anxiety. Our goal was to 
evaluate the feasibility and efficacy of using meditative virtual reality (VR) to improve 
the hospital experience of intensive care unit (ICU) patients. 
• Methods: A Google Daydream headset was used to expose ICU patients to commercially 
available VR applications focused on calmness and relaxation (Google Spotlight Stories 
and RelaxVR). Sessions were conducted once daily for up to seven days. Outcome 
measures including pain level, anxiety, depression, medication administration, sleep 
quality, heart rate, respiratory rate, blood pressure, delirium status, and patient ratings of 
the VR system were evaluated using paired t-tests and mixed models where appropriate. 
• Results: 46 participants (M = 50 years, SD = 18, 65% Male) completed the study. The 
clinical effects of VR were minimal for pain, sleep, and physiological measures. Delirium 
prevalence after VR exposure was low (13%). Most participants had strong positive 
reactions to the VR exposure and showed considerable improvements in affect over time.  
• Conclusion: The initial feasibility of exposing patients to VR in ICU was demonstrated. 
The lessons learned from deploying VR in the ICU are discussed and future avenues of 
research on the use of VR in the ICU are identified. 
• Trial registration: The trial was registered on December 29, 2017 with ClinicalTrials.gov 
with the identifier: NCT03385993.  
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Introduction 
 A patient’s stay in the intensive care unit (ICU) is often traumatic. Patients may 
experience prolonged states of immobility and sedation as part of their treatment that can lead to 
the development of ICU-acquired weakness (ICUAW) in 25%-100% of patients [1]. Disrupted 
sleep cycles, long hospital stays, and extended periods of pain put ICU patients at greater risk for 
delirium-related mortality [2]. After ICU discharge, 50%-70% of patients exhibit persistent 
cognitive dysfunction, weakness, and post-traumatic symptoms that can contribute to indefinite 
negative impacts on the patient’s finances, daily life, and need for assistance from friends and 
family [3]. 
Many of these ICU related complications are not the direct result of illness, injury, or 
medical care. In recent years, critical care professionals have raised attention to modifiable 
aspects of the ICU environment with the aim of improving the patient recovery experience [4]. 
Interventions that encouraged early and regular exercise have shown promising results for 
prevention of ICUAW in critically ill patients[5]. Clinical guidelines for delirium prevention 
emphasize strategies to orient patients, maximize comfort, minimize pain, control noise and 
light, and promote good sleep [6-8]. Although researchers and clinicians are aware of such 
modifiable risks, there are relatively few feasible strategies for mitigating these risks in the 
hospital setting given the limited resources available. 
We hypothesize that virtual reality (VR) may provide an ideal platform for controlled, 
scalable, and effective environmental manipulation in the ICU. VR uses immersive stereoscopic 
video and audio provided by a head-mounted display, which can be used in conjunction with 
tracking of the user’s hands or body to enable interaction [9]. VR has been praised for mitigating 
some of the common shortcomings of traditional therapies. VR experiences can help users feel 
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safer, more in control, and more comfortable than in-person outpatient therapy due to less 
reliance on abstract visualization and less need to present stressful real stimuli [10]. Exposure 
therapy in VR was demonstrated to be as effective as standard in-situ treatment while being 
perceived as more tolerable by patients [11]. Preoperative exposure to VR relaxation has shown 
to reduce anxiety and physiological stress measures in child and adult patients [12, 13]. Severe 
burn victims reported less pain during treatment when VR relaxation was used during wound 
debridement [14]. Medical therapy with VR has been generally efficacious and accepted by 
patients across a variety of treatment contexts. It remains important to expand the applications of 
VR towards feasible improvements to the patient’s healthcare experience [15]. 
Recommendations for optimal ICU settings encourage early exercise, comfortable room 
ambiance, pain management, and good sleep. In addition to the environmental adjustments 
provided by the healthcare team, VR may provide a system in which some of these 
recommendations can be enhanced. The purpose of this interdisciplinary study was to evaluate 
initial feasibility of VR for the relaxation of ICU patients.  
Materials and Method 
Participants and Setting 
 This study was conducted on a single-center cohort of patients admitted to the surgical or 
trauma ICU at University of Florida Health Shands Hospital, a large academic quaternary care 
facility in the Southeastern United States. All patients at the time of enrollment signed a written 
consent and were ≥18 years, tested negative for delirium using the Confusion Assessment 
Method (CAM-ICU), were not in contact isolation (e.g., at high risk of infection or contagious), 
were likely to stay in the ICU for several days (as reported by the bedside nurse), were not 
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intubated, and did not have any conditions which might limit face, head, or neck movement. The 
study was approved by the University of Florida Institutional Review Board (#IRB201703107). 
Materials 
 The Google Daydream VR system (vr.google.com/daydream) was used in this study. The 
VR system consisted of the Google Daydream headset with a hand-held controller and a 
smartphone inserted into the headset to run VR applications (Figure 1(A)). The headset with 
smartphone was lightweight (less than 1 pound) and simple to adjust for fit and comfort. We 
used Google Spotlight Stories’ Pearl (atap.google.com/spotlight-stories) as an initial orientation 
to VR and RelaxVR (www.relaxvr.co; Figure 1(B)) to provide patients with a calm immersive 
scene (e.g., beach with rolling waves) and voiced meditation instructions that promoted breath 
control and progressive relaxation. In addition to the VR headset, patients were provided with 
wireless Bluetooth earphones to provide the audio for the VR experience and reduce 
environmental noise. Both the headset and the earphones were affixed with protective sanitary 
covers. The headset, smartphone, controller, VR applications, and earphones were collectively 
referred to as the Digital Rehabilitation Environment Augmenting Medical System (DREAMS). 
Figure 1. (A) DREAMS Equipment: 1, VR sanitary mask; 2, Google Daydream headset; 3, 
Bluetooth headphones with sanitary covers; 4, Android smartphone. (B) RelaxVR menu 
screenshot. 
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Dependent Measures 
 The primary dependent measures of this study were patients’ pain, sleep quality, affect, 
delirium status, and qualitative responses to using the DREAMS. Pain was measured with the 
Defense and Veteran’s Pain Rating Scale (DVPRS) [16], sleep quality with the Richards-
Campbell Sleep Questionnaire (RCSQ) [17], affect with the Hospital Anxiety and Depression 
Scale (HADS) [18], delirium status with the Confusion Assessment Method for the Intensive 
Care Unit (CAM-ICU) [19], and patients’ qualitative responses to the DREAMS with structured 
interviews (Supplement A). Each patient’s heart rate, respiration rate, and medication logs were 
retrieved to track if VR had effects on physiology and pain. 
The CAM-ICU, DVPRS, heart rate, respiratory rate, blood pressure, and medication logs 
were recorded by healthcare staff during normal hospital treatment. These data were later 
retrieved from the University of Florida Integrated Data Repository after sessions were 
concluded. The RCSQ, HADS, and DREAMS questionnaires were administered by the 
researchers during sessions. 
Session Procedures 
The initial session began upon the patient’s agreement to participate and signature of the 
informed consent. Researchers administered the RCSQ and HADS on the first day of the study to 
establish baseline measures. Then, participants were fitted with the DREAMS and adjusted for 
their comfort. Once the DREAMS was set up, researchers initiated the Pearl VR short film (5 
min) to demonstrate the basic format of VR. Participants were instructed to freely change their 
gaze direction while enjoying the short film. Afterwards, researchers initiated the RelaxVR app 
and instructed patients to proceed through a 5-20 minute guided meditation for breath control 
and progressive relaxation. The DREAMS was removed when participants completed viewing 
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and researchers interviewed participants with open-ended questions about their experience. The 
researchers recorded audio of these patient responses for later analysis. At the end of the session, 
researchers asked participants to revisit the relaxation techniques provided by RelaxVR whenever 
they felt it could help. 
Participants received up to seven sessions in total. Each session occurred at least 24 hours 
after the previous session. Pearl was only shown during the initial session, and each subsequent 
session occurred in an otherwise identical manner. 
Data Analysis 
 Results were summarized as frequencies and percentages for categorical variables, mean 
and standard deviation for normally distributed variables, and median and interquartile ranges for 
non-normal continuous variables. Paired t‐tests with adjustments made for multiple comparisons 
were used to compare pre- and post-session numerical values. Mixed models were constructed to 
examine the changes in pain levels (DVPRS), heart rate, respiratory rate, systolic blood pressure, 
diastolic blood pressure, mean arterial blood pressure, opioid medication dosage, ‘pro re nata’ 
(PRN) opioid medication dosage, PRN opioid medication frequency, RCSQ, and HADS across 
study days taking the correlation within the same subject measurements into account. As a 
sensitivity analysis for measures collected multiple times per day, we constructed models 
comparing pre- and post-DREAMS session values within one, two, four, six, eight, and twelve 
hours of the DREAMS session. Dosages of opioids were converted to oral morphine milligram 
equivalents prior to analysis. Medications received during an operation were excluded from the 
analysis. Statistical features were extracted from time series physiological data including min, 
max, variance, and mean across study days for all time intervals. All significance tests were two‐
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sided with α < 0.05 considered statistically significant. Statistical analyses were performed with 
R v.3.6. 
Results 
Participants 
A total of 59 participants were recruited (Figure 2). Of these 59, 13 participants did not 
complete the study due to unplanned schedule changes such as emergency surgery or discharge 
from the ICU. The remaining 46 participants received either one DREAMS session (N = 17), 
two DREAMS sessions (17) or three to seven DREAMS sessions (N = 12). 
 
Figure 2. CONSORT diagram (13 did not participate due to emergency or discharge). 
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Participants in general were older adults (M = 50 years, SD = 18) and male (65%) (Table 1). 
Most participants (61%) were hospitalized emergently. The median hospital stay for all 
participants was 11 days (25th: 7,75th: 23). 
Table 1. Patient demographics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pain 
 The impacts of the DREAMS on pain were examined by comparing patients’ reported 
pain scores before and after the DREAMS sessions, patients’ perceptions about how the 
DREAMS experience affected their pain level, and opioid analgesic use before and after 
DREAMS sessions. 
Variables N=46 
Baseline Characteristics 
Age in years, mean (SD) 50 (18) 
Sex (male), n (%) 30 (65%) 
Ethnicity, n (%)  
Black 8 (18%) 
Other ethnicity 2 (4%) 
White 36 (78%) 
Admission Type, n (%) 
Emergent 28 (61%) 
Routine elective 18 (39%) 
Hospital Outcomes 
Length of stay (days), median (25th-75th) 11 (7,23) 
Discharge Disposition, n (%) 
Death 1 (2%) 
To another hospital 3 (7%) 
To home 16 (35%) 
To homecare 13 (28%) 
To other lower facility 13 (28%) 
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The Defense Veterans Pain Reporting Scale (DVPRS) is a visual analog scale where 
patients report their pain level on an integer scale from 0 (“no pain”) to 10 (pain so intense that 
“nothing else matters”). No statistically significant relationship was found between the study day 
and patient DVPRS improvement (p > 0.05). Overall, no evidence supported a clinical or 
statistical difference observed in DVPRS when comparing the average pain score in each time 
interval for each patient before and after each intervention (Figure 3). 
 
Figure 3. Mean DVPRS pain improvement before and after VR exposure. 
 Interestingly, despite patients reporting no statistically significant improvement in 
DVPRS before and after each session, 81% of patients agreed or strongly agreed with the 
statement, “I feel that I experienced less pain yesterday because of the DREAMS” (Figure 4). 
This discrepancy between patients’ objective (i.e., DVPRS) and subjective (i.e., DREAMS 
questionnaires) pain ratings could be due to confirmation bias, demand characteristics, or subtle 
effects of VR not identified in this study. Further investigation is required to examine the 
discrepancy between DVPRS and patient responses to the study questions. 
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Figure 4. Patients’ perceptions of how DREAMS decreased their pain. 
The dosage and frequency of opioid medications decreased over time at a rate of 12.9 
(95% CI 21.7, 4.03) oral morphine milligram equivalents (MMEs) per study day. No statistically 
significant changes were found when comparing dosage or frequency before and after any 
intervention. Nonetheless, the observed decreases in PRN opioid medication dosages comparing 
the preceding and proceeding 24 hours may be considered clinically significant with an average 
decrease in PRN opioid dose ranging from 54.8 MME after the first intervention to an average 
decrease of 11.5 MME after the third intervention (Table 2). 
Table 2. PRN mg of oral morphine equivalent administered 24 hours pre-post sessions. 
 
Session 
Number 
Estimated Decrease (95% 
Confidence Interval) 
1 54.8 (-41.5, 151) 
2 31.4 (-8.91, 71.7) 
3 11.5(-4.09, 27.1) 
 
 
Agree
81%
Neutral
15%
Disagree
4%
"I feel that I experienced less pain yesterday because of the DREAMS"
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Sleep 
The RCSQ is a series of questions about their last night’s rest that patients scored from 0 
to 100 (higher indicates better sleep). Participants’ sleep quality, as measured by the RCSQ, 
improved by 4.56 (95% CI 1.06, 8.06) points each study day (Figure 5), however there was no 
statistically significant difference observed when comparing successive nights sleep or baseline 
sleep quality to a given study day.  
  
Figure 
 
Figure 5. Sleep Improvement over time compared to baseline. 
 
Affect 
The Hospital Anxiety and Depression Scale (HADS) is a self-assessment scale for 
patients to estimate their current state of anxiety and depression. An anxiety or depression sub-
score of 0-7 indicates normal affect, 8-10 indicates borderline case, and 11-21 indicates 
abnormal case. We compared participants’ HADS’ sub-scores before their first DREAMS 
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exposure to their sub-scores just before their second and third exposures. There was no 
statistically significant change in anxiety (estimate = -0.808, 95% CI: -0.258, 1.87) or depression 
(estimate = -0.63, 95% CI: -0.256, 1.52) the day after the first session, however there was a 
statistically significant change in anxiety (estimate = -2.17, 95% CI: -4.23,-0.106) and depression 
(estimate = -1.25,  95% CI: -2.37,-0.129) sub-scores from the baseline value before the first 
session to the day after the second DREAMS exposure (Figure 6). Ten of the thirteen patients 
that scored in the borderline category for depression improved to within the normal range during 
the study period. No patients transitioned to a worse depression category during the study. Four 
of the ten patients in the abnormal anxiety category improved, with two of those patients 
reaching the normal range during the study period. Five of the eleven patients in the borderline 
anxiety category improved to the normal category during the study period. Three patients 
experienced an increase in anxiety during the study period. 
 
Figure 6. Hospital Anxiety and Depression (HADS) subscores for DREAMS participants. 
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Delirium 
The Confusion Assessment Method for ICU (CAM-ICU) was used to determine whether 
patients were delirious. All CAM-ICU scores were retrieved from electronic medical record data 
for each subject for the duration of their admission. Out of the 46 subjects that participated in a 
DREAMS session, 13 of them were delirious (as indicated by the patient’s chart for at least one 
day during their admission). Seven of these patients were delirious for at least one day prior to 
the study but had recovered prior to enrollment in the study. The other six patients were delirious 
after completing the DREAMS study. Of the six patients that developed delirium after 
participating in a DREAMS session, the average time between their final DREAMS session and 
delirium diagnosis was 84 hours. The average duration of these patients’ delirium post-study was 
140 hours. None of the patients that were delirious prior to participating in the study became 
delirious after participating in the study. 
Vital signs 
 Patients’ blood pressure (BP), heart rate (HR), and respiratory rate (RR) were compared 
at one, two, four, six, eight, and twelve hours before and after each DREAMS session. No 
statistically significant differences were observed in pre- vs post-session, minimum, maximum, 
mean, or variability in systolic BP, diastolic BP, mean arterial pressure, HR, or RR at any time 
interval or session number.  
Participants’ Reactions to the DREAMS 
Participants were asked to rate how much they agreed with statements about their use of 
DREAMS and to elaborate on their ratings. Participants generally liked the DREAMS. They 
agreed with statements about whether the DREAMS was comfortable to interact with (Comfort), 
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they enjoyed the use of the DREAMS (Enjoyment), the DREAMS helped them better manage 
their pain symptoms (Pain), and they thought about the DREAMS outside of our sessions 
(Reflection). However, participants were more mixed on whether DREAMS helped them sleep 
better (Sleep) (Figure 7). Transcripts of audio recordings were analyzed qualitatively to identify 
themes in participants’ responses. Several key themes emerged. 
  
Figure 7. Participants’ reaction to the DREAMS. Comfort = “I thought using the DREAMS was 
comfortable,” Enjoyment = “I liked the experience of using the DREAMS,” Pain = “I feel that I 
experienced less pain yesterday because of the DREAMS,” Reflection = “I found myself thinking 
about the DREAMS after the session was over,” Sleep = “I feel that I slept better last night 
because of the DREAMS.”  
 
 Novelty of VR. One participant had prior experience with VR, but enjoyment of the 
DREAMS was nearly universal. Participants were often observed smiling, laughing, and giving 
positive remarks during use of the DREAMS. Several participants recommended wider 
deployment of the DREAMS. “[Other ICU patients] would be crazy if they didn’t [want to try 
the DREAMS]…she was telling you how to breathe, and I could see how that could be beneficial 
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for us in here, or for anybody.” Participants enjoyed the DREAMS enough to inquire about 
purchasing options. “I was going to ask you if I could buy one,” “Is this on iPhone? You should 
put it on an app!” Participants also volunteered constructive feedback for future improvements of 
the DREAMS. Most comments involved better visuals and audio for improved immersion. “The 
waves were good, don’t get me wrong, very tranquil. But to get the authenticity of it all, you 
need [seagulls] just in the distance.” Participants were generally interested in the novelty of VR 
and expressed excitement about the potential for VR in the ICU. 
 Emotionally evocative. The immersive virtual environments depicted in Pearl and 
RelaxVR tended to evoke nostalgic memories in patients. One participant noted, “I liked the 
rocks, they remind me of the shores of Maine” while another stated that the beach scene 
reminded her of family vacations she would like to plan after discharge from the ICU. “It looks 
like Costa Rica…makes you feel like you’re there.” Some participants’ emotional reactions to 
Pearl were particularly unexpected. Pearl is a 5-min short VR film about a young girl and her 
father told from the inside of their family car. Several participants reported feeling fearful of the 
depiction. “Not safe driving…Sure tells you what not to do, when [the father] jumped into the 
back seat. He’s stupid.” Another participant noted sarcastically, “It’s funny, he’s driving while 
playing the guitar. Seems totally safe.” One participant experienced an especially negative 
emotional reaction to Pearl due to a previous experience of a loved one lost due to a car 
accident. The immersive properties of VR can be a powerful tool for health promotion. It is 
important, however, that researchers, clinicians, and developers be aware of potential negative 
reactions that can be particularly strong in VR. 
 Relaxing. Participants would often vocalize statements about relaxation during VR 
exposure and sometimes drift into sleep with the VR session running. For some participants, the 
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DREAMS provided a welcomed feeling of privacy and escape from their ICU room. Participants 
noted that “I liked that I could enjoy it [by myself]” and “[VR] is better than the TV because 
you’re there [the beach].” The DREAMS provided participants with an isolated visual and 
auditory environment to focus on their relaxation and breathing, which may have provided a 
temporary escape or distraction from their uncomfortable but necessary recovery situation. 
 Technical frustrations. Sometimes participants were provided with suboptimal VR 
experiences due to errors with the equipment or software. Adjusting the headset tightness was 
slightly more difficult for participants with longer hair. This would sometimes allow light from 
the ICU room to bleed into the screen and disrupt the viewing experience. A blinking notification 
light was unintentionally left on during one participant’s session, who later noted feeling dizzy as 
a result. Technical and procedural difficulties can contribute to participant frustration and should 
be minimized with training and preparation to provide the best experience possible. It will also 
be important to tailor VR equipment for the unique demands of the ICU, where patients can be 
physically incapable of safely or comfortably engaging with most commercially available 
options—many of which require the user to move around in circles to fully engage with the VR 
experience. 
 Temporary effects. The impacts of DREAMS on physiological measures were 
negligible and participants seemed aware of this. The DREAMS was reported to have distracted 
from pain, but only during the VR exposure section of the sessions. In response to whether 
DREAMS helped them sleep better, several participants noted that they had received medication 
that affected their sleep and made it difficult to say if the DREAMS contributed. “Unfortunately, 
it was probably the melatonin…I’m sure [DREAMS helped me sleep] because I did not have the 
same problem with my pressure and my pulse was relatively good last night.” Participants were 
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generally unsure if the DREAMS helped with pain, mostly due to the critical nature of their 
status. “I can’t tell you I [experienced less pain because of DREAMS] because yesterday was 
pretty painful.” Another participant noted, “I mean, my leg pain was real bad, so I can’t really 
put it on [the DREAMS].” Despite this, most participants still reported enjoying the DREAMS. 
When asked if the DREAMS helped with his pain, one participant responded, “Not really, but 
it’s a good part of my day.” 
Discussion 
 We demonstrated initial feasibility for use of VR relaxation in ICU patients. Despite 
finding no clinically or statistically significant effects on physiology, pain, or sleep, participants 
overwhelmingly enjoyed the VR experiences provided by the DREAMS. Our results show that 
ICU patients are eager to undergo the stimulation that VR provides and may serve as a welcomed 
distraction from unavoidable discomforts of their current medical situations. Collectively, these 
results show VR to be a promising option to help improve the ICU patient experience. 
 The DREAMS equipment was easy to set up, intuitive to use, and enjoyed by 
participants. The ICU is a busy, noisy setting in which patients of the greatest need are closely 
monitored by highly trained medical staff. Proposed additions to the ICU must be effective, 
simple, and affordable. The DREAMS consists of a smartphone running commercially available 
VR apps inserted into a headset that is worn around the head like goggles. Each component of 
the DREAMS is widely available and most people are already familiar with smartphone 
interfaces. Furthermore, the DREAMS can be quickly and easily sanitized between uses with 
common medical disinfectant wipes. Combined with participants’ enjoyment of the VR 
exposure, this makes the DREAMS and similar systems remarkably portable and an ideal 
candidate for deployment in the ICU. 
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 The primary goal of this study was to assess feasibility of VR for ICU patients’ 
experience. While we did not find clinically or statistically significant effects in health outcomes 
such as pain management, heart rate, blood pressure, or sleep quality, it should be noted that 
participants in our study only received 5-20 minutes of VR exposure each day and acute changes 
in vital signs during and after the VR experience may not have been adequately captured due to 
the limited granularity of vital signs data provided by the integrated data repository. It seems 
unlikely that 5-20 minutes of VR exposure would produce large effects on health outcomes in a 
critical care environment, but this will be an important topic to evaluate empirically in future 
research. Previous research using VR for inpatient therapy has shown that upwards of 40 minutes 
of VR for as long as 3 months can be feasibly implemented with good results [15]. There 
remains good reason to hypothesize that VR exposure can help patients better manage stress and 
discomfort in environments like the ICU [20]. 
 Participants in this study may represent selection bias. We approached ICU patients who 
were conscious, not intubated, not in isolation, and not already delirious. While VR would not be 
helpful for the unconscious or severely delirious, ICU patients who are otherwise awake should 
be included in future research as they are at the greatest risk for developing ICUAW and 
delirium. It will be important for researchers, clinicians, developers, and ICU survivors to 
collaborate in the design of VR equipment and software tailored for the ICU patient 
experience—including those who may be immobile, intubated, or in contact isolation. 
Patients in the ICU are likely to experience unease and uncertainty in their recovery. 
These patients are under constant observation and receive the best medical care available. 
However, the vast majority of their time in the ICU is spent in prolonged discomfort and 
sedentary in an austere environment. VR technologies are relatively affordable, increasingly easy 
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to use, and enjoyed by patients. Therapies in VR can be designed specifically for the needs of 
patients in the ICU to help them regain or maintain bodily control, improve stress and pain 
management, and provide a welcomed distraction from unpleasant but necessary medical 
conditions. 
Conclusion 
A virtual reality meditative intervention was found to improve patient’s experiences in 
the ICU by reducing patients’ levels of anxiety and depression; however, there was no evidence 
suggesting that VR had any significant effects on physiological measures, pain, or sleep. The use 
of VR technology in the ICU was shown to be easily implemented and well-received by patients. 
The DREAMS project demonstrates that interdisciplinary teams of medical researchers, artists, 
engineers, and psychologists can and should collaborate with emerging technologies to improve 
the ICU patient’s experience.  
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Supplement A: DREAMS Interview Procedures 
 
After completion of the virtual reality (VR) experience, a brief interview was performed to 
evaluate subjects’ perceptions of the DREAMS experience. The interview was audio recorded 
for participants that consented to audio recording. 
The interview began with the following set of instructions:  
“Please rate your agreement with the following statements on a scale from one to five, with one 
being ‘Strongly Agree’ and five being ‘Strongly Disagree’.” 
1. “I liked the experience of using the DREAMS.” 
2. “I thought using the DREAMS was comfortable.” 
3. “I found myself thinking about DREAMS after the session was over.” 
4. “I feel that I slept better last night because of the DREAMS.” 
5. “I feel that I experienced less pain yesterday because of the DREAMS.” 
The interview was concluded by providing participants the opportunity to provide open ended 
feedback. We asked the participants to “Describe in your own words what changes you would 
make to improve this experience.” 
